Literature DB >> 34503974

Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites.

Siennah R Miller1, Meghan E McGrath1, Kimberley M Zorn1, Sean Ekins1, Stephen H Wright1, Nathan J Cherrington2.   

Abstract

Equilibrative nucleoside transporters (ENTs) are present at the blood-testis barrier (BTB), where they can facilitate antiviral drug disposition to eliminate a sanctuary site for viruses detectable in semen. The purpose of this study was to investigate ENT-drug interactions with three nucleoside analogs, remdesivir, molnupiravir, and molnupiravir's active metabolite, β-d-N4-hydroxycytidine (EIDD-1931), and four non-nucleoside molecules repurposed as antivirals for coronavirus disease 2019 (COVID-19). The study used three-dimensional pharmacophores for ENT1 and ENT2 substrates and inhibitors and Bayesian machine learning models to identify potential interactions with these transporters. In vitro transport experiments demonstrated that remdesivir was the most potent inhibitor of ENT-mediated [3H]uridine uptake (ENT1 IC50: 39 μM; ENT2 IC50: 77 μM), followed by EIDD-1931 (ENT1 IC50: 259 μM; ENT2 IC50: 467 μM), whereas molnupiravir was a modest inhibitor (ENT1 IC50: 701 μM; ENT2 IC50: 851 μM). Other proposed antivirals failed to inhibit ENT-mediated [3H]uridine uptake below 1 mM. Remdesivir accumulation decreased in the presence of 6-S-[(4-nitrophenyl)methyl]-6-thioinosine (NBMPR) by 30% in ENT1 cells (P = 0.0248) and 27% in ENT2 cells (P = 0.0054). EIDD-1931 accumulation decreased in the presence of NBMPR by 77% in ENT1 cells (P = 0.0463) and by 64% in ENT2 cells (P = 0.0132), which supported computational predictions that both are ENT substrates that may be important for efficacy against COVID-19. NBMPR failed to decrease molnupiravir uptake, suggesting that ENT interaction is likely inhibitory. Our combined computational and in vitro data can be used to identify additional ENT-drug interactions to improve our understanding of drugs that can circumvent the BTB. SIGNIFICANCE STATEMENT: This study identified remdesivir and EIDD-1931 as substrates of equilibrative nucleoside transporters 1 and 2. This provides a potential mechanism for uptake of these drugs into cells and may be important for antiviral potential in the testes and other tissues expressing these transporters.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34503974      PMCID: PMC8626781          DOI: 10.1124/molpharm.121.000333

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  48 in total

Review 1.  Antibodies to watch in 2021.

Authors:  Hélène Kaplon; Janice M Reichert
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

2.  Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates.

Authors:  Philip J Sandoval; Kimberley M Zorn; Alex M Clark; Sean Ekins; Stephen H Wright
Journal:  Mol Pharmacol       Date:  2018-06-08       Impact factor: 4.436

3.  Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men.

Authors:  Joseph A Politch; Kenneth H Mayer; Seth L Welles; William X O'Brien; Chong Xu; Frederick P Bowman; Deborah J Anderson
Journal:  AIDS       Date:  2012-07-31       Impact factor: 4.177

Review 4.  Transepithelial transport across the blood-testis barrier.

Authors:  Siennah R Miller; Nathan J Cherrington
Journal:  Reproduction       Date:  2018-12       Impact factor: 3.906

Review 5.  Nucleoside transporter proteins.

Authors:  Míriam Molina-Arcas; F Javier Casado; Marçal Pastor-Anglada
Journal:  Curr Vasc Pharmacol       Date:  2009-10       Impact factor: 2.719

Review 6.  Pyronaridine: An update of its pharmacological activities and mechanisms of action.

Authors:  Christian Bailly
Journal:  Biopolymers       Date:  2020-09-10       Impact factor: 2.505

7.  Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling.

Authors:  Siennah R Miller; Xiaohong Zhang; Raymond K Hau; Joseph L Jilek; Erin Q Jennings; James J Galligan; Daniel H Foil; Kimberley M Zorn; Sean Ekins; Stephen H Wright; Nathan J Cherrington
Journal:  Mol Pharmacol       Date:  2020-12-01       Impact factor: 4.436

8.  Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data.

Authors:  Moses J Soka; Mary J Choi; April Baller; Stephen White; Emerson Rogers; Lawrence J Purpura; Nuha Mahmoud; Christine Wasunna; Moses Massaquoi; Neetu Abad; Jomah Kollie; Straker Dweh; Philip K Bemah; Athalia Christie; Victor Ladele; Oneykachi C Subah; Satish Pillai; Margaret Mugisha; Jonathan Kpaka; Stephen Kowalewski; Emilio German; Mark Stenger; Stuart Nichol; Ute Ströher; Kristin E Vanderende; Shauna Mettee Zarecki; Hugh Henry W Green; Jeffrey A Bailey; Pierre Rollin; Barbara Marston; Tolbert G Nyenswah; Alex Gasasira; Barbara Knust; Desmond Williams
Journal:  Lancet Glob Health       Date:  2016-08-30       Impact factor: 26.763

9.  Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses.

Authors:  Sean Ekins; Peter B Madrid
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

10.  Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019.

Authors:  Diangeng Li; Meiling Jin; Pengtao Bao; Weiguo Zhao; Shixi Zhang
Journal:  JAMA Netw Open       Date:  2020-05-01
View more
  9 in total

1.  The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.

Authors:  Yue Shen; William Eades; William Liu; Bingfang Yan
Journal:  Drug Metab Dispos       Date:  2022-07-05       Impact factor: 3.579

2.  The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.

Authors:  Katja Merches; Leonie Breunig; Julia Fender; Theresa Brand; Vanessa Bätz; Svenja Idel; Laxmikanth Kollipara; Yvonne Reinders; Albert Sickmann; Angela Mally; Kristina Lorenz
Journal:  Arch Toxicol       Date:  2022-05-17       Impact factor: 6.168

Review 3.  Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.

Authors:  Hong Zhou; Wei-Jian Ni; Wei Huang; Zhen Wang; Ming Cai; Yan-Cai Sun
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

Review 4.  Molnupiravir: A new candidate for COVID-19 treatment.

Authors:  Fariba Pourkarim; Samira Pourtaghi-Anvarian; Haleh Rezaee
Journal:  Pharmacol Res Perspect       Date:  2022-02

5.  A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants.

Authors:  Ching-Wen Chang; Krishna Mohan Parsi; Mohan Somasundaran; Emma Vanderleeden; Ping Liu; John Cruz; Alyssa Cousineau; Robert W Finberg; Evelyn A Kurt-Jones
Journal:  Viruses       Date:  2022-06-23       Impact factor: 5.818

6.  PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.

Authors:  Raymond K Hau; Stephen H Wright; Nathan J Cherrington
Journal:  Clin Transl Sci       Date:  2022-05-16       Impact factor: 4.438

Review 7.  Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes (SLC28 and SLC29).

Authors:  Marçal Pastor-Anglada; Aida Mata-Ventosa; Sandra Pérez-Torras
Journal:  Int J Mol Sci       Date:  2022-08-07       Impact factor: 6.208

8.  Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment.

Authors:  Amy Q Wang; Natalie R Hagen; Elias C Padilha; Mengbi Yang; Pranav Shah; Catherine Z Chen; Wenwei Huang; Pramod Terse; Philip Sanderson; Wei Zheng; Xin Xu
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

Review 9.  Computer-aided discovery, design, and investigation of COVID-19 therapeutics.

Authors:  Chun-Chun Chang; Hao-Jen Hsu; Tien-Yuan Wu; Je-Wen Liou
Journal:  Tzu Chi Med J       Date:  2022-03-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.